BRPI0606707A2 - uréias dissubstituìdas como inibidores de quinase - Google Patents

uréias dissubstituìdas como inibidores de quinase

Info

Publication number
BRPI0606707A2
BRPI0606707A2 BRPI0606707-7A BRPI0606707A BRPI0606707A2 BR PI0606707 A2 BRPI0606707 A2 BR PI0606707A2 BR PI0606707 A BRPI0606707 A BR PI0606707A BR PI0606707 A2 BRPI0606707 A2 BR PI0606707A2
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
treatment
warm
disubstituted urea
Prior art date
Application number
BRPI0606707-7A
Other languages
English (en)
Inventor
Pascal Furet
Georg Martiny-Baron
Clive Mccarthy
Vittorio Rasetti
Andrea Vaupel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606707A2 publication Critical patent/BRPI0606707A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

URéIAS DISSUBSTITUìDAS COMO INIBIDORES DE QUINASE. A presente invenção refere-se a compostos da fórmula (1), seu uso como inibidores de quinase, novas fórmulações farmacêuticas que compreendem os ditos compostos, ditos compostos para uso no diagnóstico ou tratamento terapêutico de animais de sangue quente, especialmente seres humanos, seu uso no tratamento de doenças ou para a fabricação de fórmulações farmacêuticas úteis no tratamento de doenças que respondem à modulação de atividade de quinase, sendo que os métodos de tratamento compreendem administração de ditos compostos em um animal de sangue quente, especialmente um ser humano, e processos para a fabricação de ditos compostos.
BRPI0606707-7A 2005-01-10 2006-01-09 uréias dissubstituìdas como inibidores de quinase BRPI0606707A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500435.3A GB0500435D0 (en) 2005-01-10 2005-01-10 Organic compounds
PCT/EP2006/000098 WO2006072589A2 (en) 2005-01-10 2006-01-09 Disubstituted ureas as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0606707A2 true BRPI0606707A2 (pt) 2009-07-07

Family

ID=34203857

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606707-7A BRPI0606707A2 (pt) 2005-01-10 2006-01-09 uréias dissubstituìdas como inibidores de quinase

Country Status (12)

Country Link
US (1) US20090131437A1 (pt)
EP (1) EP1838700A2 (pt)
JP (1) JP2008526804A (pt)
KR (1) KR20070097493A (pt)
CN (1) CN101103023A (pt)
AU (1) AU2006204505A1 (pt)
BR (1) BRPI0606707A2 (pt)
CA (1) CA2592743A1 (pt)
GB (1) GB0500435D0 (pt)
MX (1) MX2007008372A (pt)
RU (1) RU2007130532A (pt)
WO (1) WO2006072589A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
JP5244369B2 (ja) 2006-11-10 2013-07-24 富士フイルム株式会社 ５−アミノピラゾール誘導体の製造方法、アゾ色素
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067131A1 (en) * 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US20120157482A1 (en) * 2009-08-28 2012-06-21 Graves Iii Alan Peterson Compounds and methods
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
PT2763984T (pt) 2011-10-03 2016-07-25 Respivert Ltd 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033447A2 (en) * 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
JP6404216B2 (ja) 2012-09-11 2018-10-10 エスエルエイチ オプティマル ヘルス エルエルシーＳｌｈ Ｏｐｔｉｍａｌ Ｈｅａｌｔｈ Ｌｌｃ 歯の清掃組成物
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
DK3357919T3 (da) 2014-02-14 2020-02-17 Respivert Ltd Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412A1 (en) 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EP4084778B1 (en) 2019-12-30 2023-11-01 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155045T3 (es) * 1997-12-22 2007-02-01 Bayer Pharmaceuticals Corp. Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
AU762077B2 (en) * 1997-12-22 2003-06-19 Bayer Healthcare Llc Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
AU2003213806A1 (en) * 2002-02-25 2003-09-09 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
EP1751139B1 (en) * 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer

Also Published As

Publication number Publication date
CA2592743A1 (en) 2006-07-13
JP2008526804A (ja) 2008-07-24
MX2007008372A (es) 2007-08-21
GB0500435D0 (en) 2005-02-16
AU2006204505A1 (en) 2006-07-13
RU2007130532A (ru) 2009-02-20
US20090131437A1 (en) 2009-05-21
KR20070097493A (ko) 2007-10-04
EP1838700A2 (en) 2007-10-03
CN101103023A (zh) 2008-01-09
WO2006072589A3 (en) 2006-10-12
WO2006072589A2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
BRPI0606707A2 (pt) uréias dissubstituìdas como inibidores de quinase
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
DE602007004093D1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
BRPI0416935A (pt) derivados de diaril ureia no tratamento de doenças dependentes de quìnase de proteìna
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
BRPI0510936A (pt) formulações com liberação controlada de substáncia ativa, contendo vardenafil
BRPI0507755A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
GT200500359A (es) Compuestos organicos
BRPI0517458A (pt) derivados da xantina com atividade para o receptor hm74a
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0308196A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
DE602005023782D1 (de) Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit
SG157399A1 (en) Substituted biaryl piperazinyl-pyridine analogues
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
WO2007140383A3 (en) Spirocyclic sulfonamides and related compounds
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BRPI0509271A (pt) formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
WO2007076460A3 (en) Substituted thiazole ureas useful as inhibitors of protein kinases
BRPI0513953A (pt) métodos para tratamento de doenças ou distúrbios mediados pela ccr2
BR112021021242A2 (pt) Composições de medicamento à base de peptídeo de colágeno e dispositivos e métodos de produção e uso dos mesmos
BR0016430A (pt) Método para o tratamento e/ou prevenção da tosse em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.